Allergan Inc. Comments on the United States Department of Justice Subpoena for the Production of Documents Relating to Promotional Practices of BOTOX(R) for Therapeutic Uses

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE: AGN) today announced that it received a subpoena from the United States Department of Justice, United States Attorney’s Office for the Northern District of Georgia requesting the production of documents regarding promotional practices involving BOTOX® (botulinum toxin type A) for therapeutic indications.
MORE ON THIS TOPIC